Stanford REACH Lab, Division of Adolescent Medicine, Department of Pediatrics, Stanford University School of Medicine, CA, United States; Division of Adolescent/Young Adult Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, United States; Faculty of Pediatrics, Harvard Medical School, Boston, United States.
Department of Biomedical Data Science, Stanford University, CA, United States.
Addict Behav. 2024 Sep;156:108076. doi: 10.1016/j.addbeh.2024.108076. Epub 2024 May 28.
Few studies examine the relationship between depression and use of specific tobacco and/or cannabis products among adolescents, young adults, and adults. We determined whether the odds of depression are greater among those who used specific tobacco and/or cannabis products and among co-users of tobacco and cannabis.
Cross-sectional online survey of a national convenience sample of 13-40-year-olds (N = 6,038). The survey included depression screening and past 30-day use of specific tobacco and cannabis products (cigarettes; e-cigarettes, vaped cannabis, little cigars, cigarillos, cigars, hookah, chewing tobacco, smoked cannabis, edible cannabis, blunts). Analyses correspond to the total sample, and 13-17-, 18-24-, and 25-40-year-olds.
Among 5,281 individuals who responded to the depression screener and nine product use questions, 1,803 (34.1 %) reported co-use of at least one tobacco product and one cannabis product in the past 30 days. Past 30-day co-use was associated with higher likelihood of screening positive for depression compared to past 30-day use of tobacco-only (aOR = 1.32, 1.06-1.65; 0.006) or cannabis-only (aOR = 1.94, 1.28-2.94; <0.001). Screening positive for depression was more likely among those who reported past 30-day use of e-cigarettes (aOR = 1.56; 1.35-1.80; <0.001), cigarettes (aOR = 1.24, 1.04-1.48; 0.016), chewed tobacco (aOR = 1.91, 1.51-2.42; <0.001), and blunts (aOR = 1.22, 1.00-1.48; 0.053) compared to those who did not report past 30-day use of these products. Among the 2,223 individuals who screened positive for depression, the most used two-product combination was nicotine e-cigarettes and smoked cannabis (614 individuals, 27.6 %).
Screening positive for depression was more likely among past 30-day co-users versus past 30-day users of tobacco-only or cannabis-only. Findings suggest that prevention programs for depression and substance use address tobacco and cannabis co-use.
很少有研究调查青少年、年轻成年人和成年人中抑郁与特定烟草和/或大麻产品使用之间的关系。我们确定了使用特定烟草和/或大麻产品的人和同时使用烟草和大麻的人的抑郁几率是否更高。
对全国 13 至 40 岁人群的便利样本进行横断面在线调查（N=6038）。该调查包括抑郁筛查和过去 30 天内使用特定烟草和大麻产品（香烟；电子烟、蒸气大麻、小雪茄、小雪茄、雪茄、水烟、咀嚼烟草、吸食大麻、食用大麻、钝器）的情况。分析对应于总样本以及 13-17 岁、18-24 岁和 25-40 岁的人群。
在 5281 名对抑郁筛查和九项产品使用问题做出回应的人中，有 1803 人（34.1%）报告在过去 30 天内同时使用了至少一种烟草产品和一种大麻产品。与过去 30 天仅使用烟草（优势比[OR]=1.32，1.06-1.65；0.006）或仅使用大麻（OR=1.94，1.28-2.94；<0.001）相比，过去 30 天同时使用烟草和大麻与更高的筛查阳性抑郁几率相关。与过去 30 天未使用这些产品的人相比，过去 30 天使用电子烟（OR=1.56；1.35-1.80；<0.001）、香烟（OR=1.24，1.04-1.48；0.016）、咀嚼烟草（OR=1.91，1.51-2.42；<0.001）和钝器（OR=1.22，1.00-1.48；0.053）的人更有可能筛查出患有抑郁症。在 2223 名筛查出患有抑郁症的人中，最常用的两种产品组合是尼古丁电子烟和吸食大麻（614 人，27.6%）。
与过去 30 天仅使用烟草或仅使用大麻的人相比，过去 30 天同时使用烟草和大麻的人筛查出患有抑郁症的几率更高。研究结果表明，预防抑郁症和物质使用的计划应解决烟草和大麻的同时使用问题。
